












Please cite the Published Version

Kuikman, Megan A , McKay, Alannah KA , Minahan, Clare , Harris, Rachel , Elliott-Sale, Kirsty J , Stellingwerff, Trent , Smith, Ella S , McCormick, Rachel , Tee, Nicolin , Skinner, Jessica, Ackerman, Kathryn E  and Burke, Louise M  (2024) Effect of Menstrual Cycle Phase and Hormonal Contraceptives on Resting Metabolic Rate and Body Composition. *International journal of sport nutrition and exercise metabolism*. pp. 1-11. ISSN 1526-484X

DOI: <https://doi.org/10.1123/ijsnem.2023-0193>

Publisher: Human Kinetics

Version: Accepted Version

Downloaded from: <https://e-space.mmu.ac.uk/634732/>

Usage rights:  In Copyright

Additional Information: Accepted author manuscript version reprinted, by permission, from *International Journal of Sport Nutrition and Exercise Metabolism*, 2024, <https://doi.org/10.1123/ijsnem.2023-0193>. © Human Kinetics, Inc.

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

Effect of Menstrual Cycle Phase and Hormonal Contraceptives on Resting Metabolic Rate and
Body Composition

Megan A Kuikman¹, Alannah KA McKay¹, Clare Minahan², Rachel Harris^{3,4}, Kirsty J Elliott-Sale⁵, Trent Stellingwerff^{6,7}, Ella S Smith¹, Rachel McCormick¹, Nicolin Tee¹, Jessica Skinner⁸, Kathryn E Ackerman⁹, Louise M Burke¹

¹Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia

²Griffith Sports Science, Griffith University, Gold Coast, QLD, Australia

³Female Performance and Health Initiative, Australian Institute of Sport, Canberra, ACT Australia

⁴Perth Orthopaedic and Sports Medicine Research Institute, West Perth, WA, Australia

⁵Department of Sport and Exercise Sciences, Institute of Sport, Manchester Metropolitan University, Manchester, UK

⁶Canadian Sport Institute-Pacific, Pacific Institute for Sport Excellence, Victoria, BC, Canada

⁷Exercise Science, Physical and Health Education, University of Victoria, Victoria, BC, Canada

⁸National Rugby League, Sydney, NSW, Australia

⁹Female Athlete Program, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA

Running Head: Resting metabolic rate and menstrual cycle phase.

Address for correspondence

Megan Kuikman, Mary MacKillop Institute for Health Research,
Australian Catholic University, Melbourne, Victoria, Australia 3000

Email: Megan.Kuikman@acu.edu.au

1 Abstract (250/250)

2 The cyclical changes in sex hormones across the menstrual cycle (MC) are associated with various
3 biological changes that may alter resting metabolic rate (RMR) and body composition estimates.
4 Hormonal contraceptive (HC) use must also be considered given their impact on endogenous sex
5 hormone concentrations and synchronous exogenous profiles. The purpose of this study was to
6 determine if RMR and dual-energy X-ray absorptiometry (DXA) body composition estimates
7 change across the MC and differ compared to HC users. This was accomplished during a 5-week
8 training camp involving naturally cycling (NC) athletes (n=11) and HC users (n= 7 subdermal
9 progestin implant, n= 4 combined-monophasic oral contraceptive pill, n=1 injection) from the
10 National Rugby League Indigenous Women's Academy. MC phase was retrospectively confirmed
11 via serum estradiol and progesterone concentrations and a positive ovulation test. HC users had
12 serum estradiol and progesterone concentrations assessed at the time point of testing. Results were
13 analyzed using general linear mixed model. There was no effect of MC phase on absolute RMR
14 ($p=0.877$), relative RMR ($p=0.957$), or DXA body composition estimates ($p>0.05$). There was no
15 effect of HC use on absolute RMR ($p=0.069$), relative RMR ($p=0.679$), or fat mass estimates
16 ($p=0.766$), but HC users had a greater FFM and LBM than NC athletes ($p=0.044$). Our findings
17 suggest that RMR and DXA body composition estimates do not significantly differ due to changes
18 in sex hormones in a group of athletes, and measurements can be compared between MC phases
19 or with HC usage without variations in sex hormones causing additional noise.

20

21 Keywords: female athletes, sex hormones, RMR

22 **Introduction**

23 There is increasing awareness that sports nutrition guidelines are predominantly based on research
24 that has been conducted in men and may not always be suitable or optimal for female athletes
25 (Costello et al., 2014; Kuikman, McKay, et al., 2023; Kuikman, Smith, et al., 2023; Smith et al.,
26 2022). A key consideration for female athletes is whether these guidelines need to account for
27 changes in circulating estrogen and progesterone concentration that occur across the menstrual
28 cycle (MC) or with hormonal contraceptive (HC) use (Elliott-Sale et al., 2021). One area of
29 interest involves metabolic rate, which has significance in contributing to the female athlete's
30 energy requirements as well as playing a potential role in assessing her energy status (Sterringer
31 & Larson-Meyer, 2022).

32

33 Resting metabolic rate (RMR) represents the minimal energy cost of living (Hulbert & Else, 2004)
34 and makes up one of the components of total daily energy requirements (Trexler et al., 2014). A
35 2020 meta-analysis of studies involving non-athlete populations found a significant small effect
36 favouring an increased RMR during the luteal compared to the follicular phase of the MC,
37 suggesting an increase in energy expenditure with elevated concentrations of progesterone and
38 estrogen (Benton et al., 2020). However, the unique hormonal profiles within the follicular and
39 luteal phase of the MC are rarely comprehensively assessed, with most studies simply comparing
40 the early-mid follicular phase of the MC (with theoretically low estrogen and progesterone
41 concentrations) to the mid-luteal phase (with theoretically elevated estrogen and progesterone
42 concentrations) (Elliott-Sale et al., 2021). Results of this specific meta-analysis are further limited
43 by inclusion of studies with poor methodological control of ovarian hormones (Benton et al.,
44 2020). Finally, given the high prevalence of hormonal contraceptives (HC) use by athletes (Martin

45 et al., 2018; McNamara et al., 2022; Oxfeldt et al., 2020) and their associated effects on
46 endogenous sex hormone concentrations and synchronous exogenous profiles (Elliott et al., 2005;
47 Hirschberg, 2022), the effects of HC use on RMR should also be assessed.

48

49 Although the practical relevance of meaningful differences in RMR on energy requirements of
50 athletes needs to be considered, another scenario for the measurement of RMR in sports nutrition
51 involves its potential use as a screening tool for metabolic suppression in response to low energy
52 availability (LEA) (Sterringer & Larson-Meyer, 2022). This is done either by determining the
53 ratio of measured RMR against a value predicted by an equation (Schofield et al., 2019), or by
54 expressing measured RMR relative to fat free mass (FFM) (Loucks et al., 2011). Although the
55 RMR ratio (measured:predicted) appears to have some utility in identifying female athletes with
56 indices of metabolic suppression (Strock et al., 2020), it has not been recognized as a primary or
57 secondary indicator of Relative Energy Deficiency in Sport (REDs) in the IOC REDs Clinical
58 Assessment Tool - Version 2 (CAT2) due to current concern around its specificity and sensitivity
59 (Stellingwerff et al., 2023). Part of this concern relates to known technical and biological
60 variability in RMR measurements (Siedler et al., 2023), the latter of which could include the effects
61 of endogenous and exogenous sex hormone concentrations. Better understanding of this variability
62 might help to improve the interpretation of RMR measurements and their use as a diagnostic tool.
63 Accordingly, the aim of this study was to investigate the effects of MC phase and HC usage on
64 RMR in a cohort of female athletes using Best Practice Guidelines for the control of ovarian
65 hormones (Elliott-Sale et al., 2021). Additionally, we measured changes in body composition
66 estimates using dual-energy X-ray absorptiometry (DXA) across MC phase and with HC usage as
67 DXA scans are often performed alongside RMR measurements to interpret findings.

68

69 Methods**70 *Participants***

71 The participants of this study are part of a larger study known as the Female Athlete Research
72 Camp (FARC) with 25 female athletes (McKay et al., 2022) being recruited for a 5-week training
73 camp at the Australian Institute of Sport, as previously described (McKay et al., 2023). Athletes
74 were from the National Rugby League's Indigenous Women's Academy and of Tier 3 calibre
75 (Highly trained/National level) (McKay et al., 2022). Both naturally cycling (NC) athletes and HC
76 users were included. Data from two HC users were excluded from analysis— one for failure to
77 complete the training camp and one for failure to comply with the standardized protocol for body
78 composition and RMR measurements. Information on the remaining NC athletes (n=11) and HC
79 users (n=12) is summarized in Table 1. Of the HC users, seven used a subdermal progestin implant
80 (Implanon), four used combined-monophasic version of the oral contraceptive pill (COC), and one
81 used hormonal injection (depot medroxyprogesterone acetate). The hormonal compositions of the
82 HC can be found elsewhere (McKay et al., 2023). The study was approved by the Human Ethics
83 Research Committee at Australian Catholic University (2021-285H).

84

-Table 1-

85 *Experimental design*

86 NC athletes tracked their MC for 11 weeks prior to study commencement, using an online reporting
87 system (REDCap). This also involved confirming ovulation via urinary luteinising hormone (LH)
88 surge testing (Elliott-Sale et al., 2021) with urinary ovulation kits (Advanced Digital Ovulation
89 Test, Clearblue, Geneva, Switzerland). NC athletes tested for ovulation from day 8 of the MC until
90 ovulation occurred or until day 17, if ovulation was not detected (McKay et al., 2023). This

91 information was used to prospectively plan testing dates for three physiologically-specific MC
92 phases (Elliott-Sale et al., 2021) during the training camp (see Figure 1): 1) Phase 1: begins at the
93 onset of bleeding, when estrogen and progesterone concentrations are low; 2) Phase 2: 14-26 hours
94 prior to ovulation and the LH surge, when estrogen concentrations are at their highest and
95 progesterone concentrations remain low; and 3) Phase 4: Seven days after ovulation when
96 progesterone concentrations are at their highest and estrogen concentration are also elevated. To
97 anticipate the day of Phase 2 during the training camp, NC athletes used dual hormone ovulation
98 kits (Advanced Digital Ovulation Test, Clearblue, Geneva, Switzerland) with a rise in estrogen
99 prior to a rise in LH being identified with a “flashing smile.” Venous blood samples were taken
100 on the day of testing, and concentrations of estrogen and progesterone were retrospectively used
101 to confirm that testing occurred at the correct MC phase. HC users were tested on three occasions
102 spaced by 7-10 days (also referred to as “Phase 1”, “Phase 2”, and “Phase 4”). COC users were
103 tested on active pill-taking days to avoid the withdrawal bleed and athletes taking all other types
104 of HC (implant and injection) were tested at any time given the continuous nature of these
105 contraceptives. HC users also had serum estradiol and progesterone concentrations at the time
106 point of testing established. Further details regarding the MC tracking can be found elsewhere
107 (McKay et al., 2023).

108 -Figure 1-

109 ***Dietary control***

110 As confirmation of MC phase was dependent on menstrual reporting that occurred mid-morning,
111 a standardized diet was implemented from lunch onwards to prepare for the next day’s laboratory
112 testing. Thus, participants consumed an *ad libitum* breakfast, with the controlled diet thereafter
113 providing 80% of their estimated requirements, which were set as $5 \text{ g} \cdot \text{kg body mass (BM)}^{-1} \cdot \text{day}^{-1}$

114 of carbohydrate, $1.5 \text{ g} \cdot \text{kg BM}^{-1} \cdot \text{day}^{-1}$ or protein, and $1 \text{ g} \cdot \text{kg BM}^{-1} \cdot \text{day}^{-1}$ as fat. For athletes with a
115 body mass index (BMI) $>110\%$ of 25.0 kg/m^2 ($n=3$ NC athletes, $n=5$ HC users), an adjusted BM
116 (ABM) was used to calculate dietary needs to prevent excessive energy intake (Krenitsky, 2005).
117 ABM was calculated as: $(\text{actual BM} - \text{ideal BM}) \times 0.25 + \text{ideal BM}$ with ideal BM representing a
118 BM that would equate to a BMI of 25.0 kg/m^2 . Diets were designed by a dietitian and prepared by
119 professional chef with all meals being weighed and provided in a dining hall setting. The dining
120 hall had a rotating 2-week menu, so athletes did not necessarily receive the same food during each
121 standardized diet period that preceded testing. Meals were supervised by a member of the research
122 team, but snacks were consumed throughout the day without supervision. Athletes self-reported
123 any deviations from standardized diets, and this was accounted for when analysing standardized
124 diets.

125

126 ***Measurements***

127 *Body composition*

128 On test mornings, athletes arrived at the laboratory in an overnight fasted and rested state such that
129 no food or fluid was consumed, or exercise was performed prior to testing. DXA was used to assess
130 body composition, using the Best Practice Protocols of the Australian Institute of Sport involving
131 standardized positioning (Slater et al., 2023). Athlete scans were performed in the same mode (GE
132 Lunar iDXA) and analyzed using GE encore by the same trained researcher to assess FFM, lean
133 body mass (LBM), and fat mass (FM). Data from the first and last DXA scan were used to assess
134 changes in body composition over the training camp.

135

136 *Resting metabolic rate*

137 RMR was determined either immediately before or after the DXA scan. As such, athletes were
138 overnight fasted and rested. A protocol of rest and familiarisation was used, which produces
139 comparable results to RMR measured in an inpatient setting and has good interday reliability (ICC
140 0.87; Typical error as CV 5.9%)(Bone & Burke, 2018). With this protocol, athletes first rested on
141 a bed in a dark and quiet room for 10 minutes before being given a one-way mouthpiece (bite size
142 rubber mouthpiece connected to silicone diaphragm that allows flow in one direction only through
143 a valve) for a 15-minute familiarisation period. Athletes were instructed not to fall asleep during
144 the measurement, and this was verbally confirmed following the measurement. The room was
145 temperature controlled, and athletes had access to a blanket during the measurement so that they
146 were at a comfortable temperature. Following the rest and familiarisation period, expired air was
147 collected into a gas-impermeable Douglas bag for 10 minutes for two consecutive data collection
148 periods. Ametek Oxygen (O₂) and carbon dioxide (CO₂) analyzers (VacuMed, Ventura, CA) were
149 calibrated with two known gas concentrations (14.38% O₂, 2.510% CO₂; and 16.30% O₂, 4.173%
150 CO₂) before use. The expirate from each bag was sampled for one minute with the gas sampling
151 time and flow rate being recorded. The volume of the remaining expirate was then determined
152 using a Tissot spirometer via an evacuation pump. RMR results were reported as absolute over 24
153 hours (kcal·day⁻¹) for each Douglas bag and then a mean RMR was computed from the two
154 Douglas bags. RMR results were also reported relative to FFM (kcal·kg FFM⁻¹·day⁻¹). It was not
155 possible to control pre-trial exercise since scheduled team training took place each afternoon
156 during the camp, but >12 hours separated training and laboratory testing. Training sessions
157 included gym or fielding sessions with duration and rating of perceived exertion (RPE) being used
158 to calculate training load (RPE x duration).

159

160 *Indicators of low energy availability*

161 At each testing time point across the camp, a RMR ratio (measured:predicted) was calculated using
162 three RMR predictive equations as outlined in Table 2 (Cunningham, 1982, 1991; Harris &
163 Benedict, 1918). These predictive equations were selected as they have validated thresholds to
164 indicate energy deficiency with an athlete being classified as having a suppressed RMR if the ratio
165 fell below this threshold (see Table 2)(Strock et al., 2020), and/or presented with a relative RMR
166 $<30 \text{ kcal}\cdot\text{kg FFM}^{-1}\cdot\text{day}^{-1}$ (Loucks et al., 2011). Alongside screening for a suppressed RMR, blood
167 indicators of LEA as per the updated IOC REDs CAT2 were measured (Stellingwerff et al., 2023)
168 and athletes completed the Low Energy Availability in Females Questionnaire (LEAF-Q) prior to
169 commencing the study (Melin et al., 2014).

170 -Table 2-

171 *Blood samples*

172 Following the DXA scan and RMR measurement, an 8.5 mL venous blood sample was collected
173 from an antecubital vein into a serum separator tube by a trained phlebotomist. Blood tubes were
174 left to clot at room temperature for 30 minutes, prior to centrifugation at 2200 G for 10 minutes at
175 4 °C. Remaining serum was split into aliquots and stored at -80 °C until batch analysis could occur.
176 Estradiol and progesterone were measured via an Access 2 Immunoassay System (Beckman
177 Coulter, Brea, CA, USA) and used to retrospectively confirm MC phase and to establish hormonal
178 profiles for HC users. Intra-assay coefficient of variations were 5% for estradiol and 11% for
179 progesterone. Lipids, cortisol, insulin-like growth factor 1 (IGF-1) and triiodothyronine (T3) were
180 measured by chemiluminescent immunoassay through a commercial laboratory (Lavery
181 Pathology, Bruce, ACT, Australia).

182

183 *Statistics*

184 Statistical analyses were performed using R Studio (v3.5.2) with statistical significance accepted
185 at an α level of $p \leq 0.05$ using general linear mixed models. Fixed effects for the model included
186 MC phase and menstrual status (NC athletes or HC users). Subject ID and test order were included
187 as random effects within the models. The initial model included all possible interactions, with non-
188 significant interactions being dropped. Statistical significance of the fixed effect was determined
189 using a Type II Wald tests with Kenward-Roger degrees of freedom, and where significant fixed
190 effects were evident, a Tukey's post-hoc comparison was used to identify where differences exist.
191 For NC athletes only, a repeated measures correlation was used to assess the relationship between
192 changes in relative RMR and serum concentrations of estradiol, progesterone, and the ratio of
193 estradiol to progesterone. Non-normally distributed data (absolute RMR, FM, estradiol levels, and
194 progesterone levels) were log-transformed for statistical analyses.

195

196 **Results**

197 Assessment of actual intake of the ~18 hour standardized diet showed no difference between trials
198 or groups for energy and macronutrient intake ($p > 0.05$) with actual intake achieving the
199 standardized diet targets (Table 3). Over the training camp, FM was reduced in both NC athletes
200 and HC users (~0.5 kg; $p = 0.0001$). FFM increased in HC users (+0.9 kg; $p < 0.0001$), but not in NC
201 athletes (+0.2 kg; $p = 0.770$). There was no difference in training load the day prior to testing with
202 MC phase ($p = 0.331$), but NC athletes had a greater training load than HC users (455 ± 308 AU vs.
203 287 ± 325 AU; $p = 0.042$).

204

-Table 3

205 Comprehensive results of menstrual status confirmation from ovulation testing and retrospective
206 analysis of serum estradiol and progesterone concentrations have been previously reported
207 elsewhere (McKay et al., 2023). In summary, five NC athletes were identified as having a
208 menstrual irregularity during the training camp (n=3 oligomenorrheic, n=1 anovulatory, n=1 luteal
209 phase deficiency). Of the remaining 6 NC athletes, only one presented with the expected Phase 2
210 hormonal profile. Thus, Phase 2 metrics were not analyzed due to the measurement variability.
211 Furthermore, Phase 1 versus Phase 4 analysis excluded data due to an insufficient rise in serum
212 progesterone concentrations from Phase 1 to Phase 4 of the MC (n= 3 NC athlete), technical issues
213 with RMR measurements (n=1 NC athlete, n= 1 HC user), and an erroneous serum estradiol
214 measurement ($>3SD$ above mean, n=1 HC user). For the remaining athletes, as expected, there
215 was an increase in serum estradiol and progesterone concentrations from Phase 1 to Phase 4 in NC
216 athletes (estradiol, $p=0.0003$; progesterone, $p<0.0001$), but not in HC users (estradiol, $p=0.967$;
217 progesterone, $p=0.323$; Table 4).

218 -Table 4-

219 There was no effect of MC phase ($p=0.877$) or HC usage ($p=0.069$) on absolute RMR nor was
220 there an effect of MC phase ($p=0.957$) or HC usage ($p=0.679$) on relative RMR (Figure 2).

221 -Figure 2-

222 There was no effect of MC phase ($p=0.118$) or HC usage ($p=0.766$) on FM estimates. While there
223 was also no effect of MC phase on FFM estimates ($p=0.225$) and LBM estimates ($p=0.248$), HC
224 users had a greater FFM ($p=0.028$) and LBM ($p=0.028$) than NC athletes (Figure 3).

225 -Figure 3-

226 There was no within athlete correlation between changes in relative RMR and estradiol
227 concentrations ($r=0.31$, $p=0.179$); progesterone concentrations ($r=0.06$, $p=0.805$), or the ratio of

228 concentrations of estradiol to progesterone ($r=0.11$, $p=0.640$) from Phase 1, Phase 2, and Phase 4
229 of the MC in NC athletes (Figure 4).

230 -Figure 4-

231 There was no effect of MC phase on the RMR ratio calculated from the Harris Benedict (HB)
232 equation using actual BM ($p=0.958$) or ABM ($p=0.141$), Cunningham₁₉₈₀ equation ($p=0.865$), or
233 Cunningham₁₉₉₁ equation ($p=0.831$) nor was there an effect of HC usage on the RMR ratio
234 calculated from the HB equation using actual BM ($p=0.398$), Cunningham₁₉₈₀ equation ($p=0.911$),
235 or Cunningham₁₉₉₁ equation ($p=0.714$; Table 5). However, the RMR ratio calculated from the HB
236 equation using ABM was greater in HC athletes than NC athletes ($p=0.020$).

237 -Table 5-

238 At the first testing measurement, no athlete presented with a suppressed RMR. However, at the
239 second and/or third test, six athletes presented with a relative RMR <30 kcal·kg FFM⁻¹·day⁻¹ and
240 one of these athletes also presented with a RMR ratio <0.90 when using the HB equation (Figure
241 5). No athlete presented with an RMR ratio considered suppressed when using the Cunningham₁₉₈₀
242 or Cunningham₁₉₉₁ equation or when using ABM in the HB equation.

243 -Figure 5-

244 **Discussion**

245 Our results showed that assessments of RMR and DXA-derived body composition estimates did
246 not differ due to changes in ovarian hormones in a group of female athletes. Specifically, there
247 were no systematic differences in RMR and DXA-derived body composition between Phase 1 and
248 Phase 4 of the MC or with HC usage in female athletes, nor any correlation with changes in
249 absolute or ratios of concentrations of serum estradiol and progesterone. These findings have
250 implications for the dietary recommendations given to female athletes and the Best Practice

251 Protocols for the measurement of RMR and body composition. Specifically, our results suggest
252 female athletes do not need to alter their energy requirements due changes in RMR across MC
253 phase or with HC use, and that MC phase and HC use does not need to be standardized when
254 measuring RMR.

255
256 Previous studies have provided some evidence for a modulation of RMR due to alterations in
257 estrogen concentrations. For example, the suppression of serum estrogen and progesterone to
258 postmenopausal concentrations in premenopausal women was associated with a ~40 kcal/day
259 reduction (~3%) in RMR compared to the follicular phase and ~70 kcal/day (~5%) compared to
260 the luteal phase (Day et al., 2005). Furthermore, this reduction in RMR was prevented with
261 concurrent transdermal estrogen administration that maintained serum estrogen concentrations to
262 that expected in the mid to late follicular phase of the MC (Melanson et al., 2015). Such effects of
263 estrogen increasing RMR have been attributed to estrogen increasing brown adipose tissue (BAT)
264 activity both directly by acting on BAT and through its effect on the ventromedial hypothalamus
265 nucleus and sympathetic nervous system signalling (Gavin et al., 2018; Vigil et al., 2022). In the
266 current study, despite the large increase in serum estradiol concentrations during Phase 4 of the
267 MC in NC athletes (Table 4), we did not show an effect of MC phase or HC usage on RMR.
268 Furthermore, a repeated measures correlation did not show any association between RMR and
269 estradiol concentrations. These findings suggest that estrogen did not achieve a significant
270 modulation of RMR in our cohort of female athletes.

271
272 Several explanations might underpin the discrepancies between our results and other studies
273 showing an increase in RMR with elevated estrogen concentrations. Firstly, any variation in RMR

274 due to sex hormones may be overshadowed by other factors that contribute to the 3-5% day-to-
275 day variability in measured RMR (Compher et al., 2006). Although precautions were taken in this
276 study to minimize factors that may contribute to technical error and variability in RMR (e.g.,
277 standardizing dietary intake the day prior to testing), consideration should be given to the
278 magnitude of change in RMR across the MC reported in previous studies. For instance, a female
279 athlete with an absolute RMR of 1200-1800 calories/day would require a change >60-90
280 calories/day to exceed a 5% day-to-day variation in RMR. Yet, of the seventeen studies in the 2020
281 meta-analysis that undertook testing in a fasted and rested state and provided RMR results, the
282 mean change in RMR was ~45 calories/day, with only five studies reporting an increase >60
283 calories/day above the follicular phase (Benton et al., 2020). Since the publication of this meta-
284 analysis, only one study could be located that found differences in RMR between MC phases with
285 RMR being 37 calories/day lower in the follicular compared to the luteal phase of the MC (Malo-
286 Vintimilla et al., 2023). However, ovulation was not confirmed, and nine of the nineteen
287 participants had serum progesterone concentrations <5 ng/mL in the luteal phase, which suggests
288 anovulatory cycles (Malo-Vintimilla et al., 2023). Furthermore, these studies were not conducted
289 specifically in athletic cohorts whom may have a greater prevalence of menstrual disturbances (De
290 Souza et al., 2010) and a greater exercise energy expenditure and energy intake resulting in a
291 greater energy flux compared to sedentary individuals (Bullough et al., 1995; Goran et al., 1994;
292 Paris et al., 2016). Interestingly, an increased RMR seen during periods of high energy flux, and
293 with elevated serum estrogen and progesterone concentrations are both thought to occur via beta-
294 adrenergic support of RMR (Bell et al., 2004; Day et al., 2005). Modulations in RMR due to
295 energy flux and sex hormones may not be additive, resulting in changes in RMR across the MC in
296 sedentary females, but not trained female athletes. Furthermore, variations in training or

297 competition prior to RMR measurements may contribute to greater variability in the RMR
298 measurements of female athletes compared to sedentary women.

299

300 A further reason for discrepancy between our results and previous studies that have demonstrated
301 changes in RMR across MC phase might be attributed to differences in methodology used to
302 identify MC phase. Few studies assessing changes in RMR across the MC have confirmed
303 ovulation and measured serum concentrations of estradiol and progesterone, which could result in
304 measurements that are occurring unknowingly in an incorrect phase and hormonal profile. For
305 instance, a common strategy is to assume that ovulation occurred half-way through the MC without
306 confirming an LH surge has occurred despite follicular phase length being variable (Mihm et al.,
307 2011). If ovulation is assumed to occur at day 14 of the MC, but a woman has an extended follicular
308 phase, measurements that are thought to have occurred in the luteal phase could actually have
309 occurred in the late follicular phase of the MC. This is problematic as these phases have different
310 hormonal profiles (Elliott-Sale et al., 2021). This technique also does not consider anovulatory
311 cycles or luteal phase defects, which will result in an incorrect hormonal profile during the luteal
312 phase of the MC (De Souza, 2003). Evidently, when assessing changes across MC phase it is vital
313 to follow the Best Practice Protocols for control of ovarian hormones (Elliott-Sale et al., 2021). It
314 should be noted that while a strength of our study was following the Best Practice Protocols for
315 ovarian hormone control, this contributed to a small sample size, which is a notable limitation of
316 our study.

317

318 The effect of hormonal profiles seen in Phase 2 of the MC on RMR could not be assessed in this
319 study. Because this phase lasts only 12-26 hours (Elliott-Sale et al., 2021), may be absent if the

320 athlete has an anovulatory cycle, and requires resources to ascertain its presence (i.e. blood sample
321 analysis to determine estrogen and progesterone concentrations, measuring for a LH surge etc),
322 there is little utility in considering its effect on nutrition recommendations for female athletes.
323 However, since Phase 2 of the MC provides an opportunity to investigate the effects of estrogen
324 on RMR with minimal progesterone (Elliott-Sale et al., 2021), this would provide mechanistic
325 insight into the control of RMR. Furthermore, the identification of any meaningful noise in RMR
326 measurement could be taken into account when Best Practice Protocols for RMR assessment in
327 athletic cohorts are established. Therefore, future studies are needed to assess if RMR changes
328 across Phase 2 of the MC, so that the need to control for this phase of the MC can be determined.

329
330 There are multiple forms of HC with unique effects on the endogenous hormonal milieu (Elliott-
331 Sale et al., 2021). Among our study cohort, 3 different types of HC (COC, injection and implant)
332 were used, with a further differentiation in the brands of COC (4 brands). The hormonal profile of
333 HC users established in this study demonstrated variations in sex hormones across testing time
334 point with a ~20% increase in estradiol concentrations and ~70% increase in progesterone
335 concentrations from “Phase 1” to “Phase 4”(Table 4). Notably, endogenous concentrations of
336 estradiol and progesterone were measured, and exogenous sex hormones may have higher receptor
337 affinity that exceed the effects of endogenous sex hormones (Hirschberg, 2022). Additionally,
338 such changes in sex hormones for HC users were small in comparison to the large increases in
339 concentrations of estradiol (~500%) and progesterone (~2900%) seen from Phase 1 to Phase 4 in
340 NC athletes. HC usage had no effect on RMR such that RMR did not differ between NC athletes
341 and HC users or between testing time points in HC users. This is in agreement with the majority
342 of studies comparing the RMR of COC users and non-users (Duhita et al., 2017, 2019; Eck et al.,

1997; Jensen & Levine, 1998), although one study reported a higher RMR in COC users when FFM and FM were included as covariates (Diffey et al., 1997). Like COC, most studies examining the effects of depot-medroxyprogesterone acetate injection on RMR have found no effect on RMR (Pelkman et al., 2001; Steward et al., 2016), and reports of changes in RMR with usage are likely secondary to changes in body composition (Batista et al., 2017). Notably, seven athletes in our cohort used the hormonal implant, Implanon, which is a single-rod progestin-only implant that is inserted in the upper arm for up to three years (Fischer, 2008). No study could be located assessing the effect of Implanon on RMR, which likely reflects the relatively new approval of this HC and usage trends compared to other HC (King et al., 2021). Overall, our study suggests that HC usage has no effect on RMR. However, a limitation of this study was the lack of homogeneity with the type of HC used within our cohort leading to an increased variability in endogenous and exogenous hormonal profiles. As such, further studies are needed to assess the effect of HC usage on RMR.

Estimates of total body composition using DXA depend on the assumption of a constant lean soft tissue hydration (Pietrobelli et al., 1996), but this will vary with extracellular and intracellular fluid distribution (St-Onge et al., 2004). Variations in sex hormones with MC phase or HC usage may introduce a source of error in DXA body composition estimates as estrogen and progesterone cause a shift in osmoregulation that may alter water distribution within the extracellular fluid space (Stachenfeld, 2008). Differences in FM estimates by DXA scan have been reported in the early versus mid-follicular phase (~0.30 kg, ~1.6% change)(Gould et al., 2021) and the late follicular phase compared with the early follicular phase (~0.31 kg, ~1.9%) and mid-luteal phase (~0.35 kg, ~2.1%)(Thompson et al., 2021). However, this is not a consistent finding with others reporting no difference between the mid-luteal and mid-follicular MC phase (Jürimäe et al., 2011; Koşar et al.,

2022; Ong et al., 2022). Additionally, for studies that have reported differences across MC phase, this difference was below the ~4.7% least significant change (LSC) in consecutive day precision error for whole body FM DXA estimates (Slater et al., 2023). Differences in DXA body composition estimates have also been reported across the oral contraceptive pill (OCP) cycle of monophasic COC users with lower LBM estimates during the early hormone phase compared to the non-active pill phase (~0.29 kg, ~0.7% change) and late pill phase (~0.34 kg, ~0.9% change) (Thompson et al., 2021). We were unable to assess change across the OCP cycle of the four COC users as all purposefully manipulated their cycles to avoid a withdrawal bleed during the camp (McKay et al., 2023). However, like FM estimates across MC phase, differences in DXA body composition previously reported across the OCP cycle were below the ~1.4% LSC in consecutive day precision error for LBM DXA estimates (Slater et al., 2023). Overall, our findings suggest that any underlying shifts in fluid balance due to changing sex hormones with MC phase and HC usage are not sufficient to produce meaningful change in DXA body composition estimates (Figure 3). Practically, this suggests researchers and practitioners can measure total body composition via a DXA scan in Phase 1 or Phase 4 of the MC without sex hormones creating additional noise.

Subtle menstrual disturbances were identified in five NC athletes within this cohort (Figure 5), and it is possible that this was due to LEA exposure (De Souza, 2003). While a suppressed RMR has been demonstrated in female athletes with menstrual disturbances (Koehler et al., 2016; Melin et al., 2015; Myerson et al., 1991; Strock et al., 2020), none of the athletes with menstrual irregularity during the training camp presented with an RMR measurement that met any of the criteria suggesting RMR suppression. This suggests either that the menstrual issues observed were not underpinned by exposure to LEA or that RMR assessment does not provide a universal tool to

389 diagnose metabolic suppression. Of the six athletes who did present with a suppressed RMR
390 measurement across the training camp, only two also presented with an indicator of LEA.
391 Furthermore, for five of the six athletes, this suppressed RMR was based solely on a relative RMR
392 $<30 \text{ kcal}\cdot\text{kgFFM}^{-1}\cdot\text{day}^{-1}$. The use of relative RMR to indicate metabolic suppression may not be
393 appropriate for the physique characteristics within this cohort of athletes, as the RMR to FFM ratio
394 changes with anthropometrics such that there is a reduced ratio with an increased BM and FFM
395 (Cameron et al., 2002; Weinsier et al., 1992). The use of RMR measurements to diagnose LEA
396 should be used with caution and alongside other markers until Best Practice Methods for the
397 measurements of RMR are developed.

398

399 ***Conclusion***

400 In conclusion, the results of this study suggest that RMR and body composition estimates do not
401 significantly differ between Phase 1 and Phase 4 of the MC or with HC use in female athletes.
402 Accordingly, measurements of RMR and body composition via DXA can be compared in Phase 1
403 or Phase 4 of the MC, or varying HC approaches in female athletes, without variations in sex
404 hormones or shifts in fluid balance causing additional noise. Furthermore, female athletes do not
405 need to purposefully alter energy intake during Phase 1 or Phase 4 of the MC or with HC usage
406 to address changes in RMR and should continue to focus on matching energy intake with
407 nutritional goals and training/competition need. Finally, as subtle menstrual irregularities are
408 difficult to identify, tracking of MC phase for clinical or research activities should not assume that
409 an athlete is within a particular phase of the MC unless confirmed using Best Practice Guidelines
410 (Elliott-Sale et al., 2021).

411

412 **Authorship**

413 This study was designed by M.A. Kuikman, A.K.A. McKay, R. Harris, C. Minahan, and L.M.
414 Burke. Data was analyzed and collected by M.A. Kuikman, A.K.A. McKay, E.S. Smith, R.
415 McCormick, N. Tee, and L.M. Burke. The data interpretation and manuscript preparation were
416 undertaken by M.A. Kuikman, A.K.A. McKay, R. Harris. K.J. Elliott-Sale, T. Stellingwerff, E.S.
417 Smith, R. McCormick, N. Tee, C. Minahan, J. Skinner, K.E. Ackerman, L.M. Burke.

418 **Funding:** This study was embedded within the Female Athlete Research Camp, and was co-
419 funded by Australian Catholic University, Wu Tsai Human Performance Alliance and the
420 Australian Institute of Sport Female Performance and Health Initiative.

421 **Conflict of interest:** The authors declare no conflict of interests.

References

- Batista, G. A., de Souza, A. L., Marin, D. M., Sider, M., Melhado, V. C., Fernandes, A. M., & Alegre, S. M. (2017). Body composition, resting energy expenditure and inflammatory markers: Impact in users of depot medroxyprogesterone acetate after 12 months follow-up. *Archives of Endocrinology and Metabolism*, *61*(1), 70–75. <https://doi.org/10.1590/2359-3997000000202>
- Bell, C., Day, D. S., Jones, P. P., Christou, D. D., Petitt, D. S., Osterberg, K., Melby, C. L., & Seals, D. R. (2004). High energy flux mediates the tonically augmented β -adrenergic support of resting metabolic rate in habitually exercising older adults. *Journal of Clinical Endocrinology and Metabolism*, *89*(7), 3573–3578. <https://doi.org/10.1210/jc.2003-032146>
- Benton, M. J., Hutchins, A. M., & Dawes, J. J. (2020). Effect of menstrual cycle on resting metabolism: A systematic review and meta-analysis. *PLoS ONE*, *15*(7), e0236025. <https://doi.org/10.1371/JOURNAL.PONE.0236025>
- Bone, J. L., & Burke, L. M. (2018). No difference in young adult athletes' resting energy expenditure when measured under inpatient or outpatient conditions. *International Journal of Sport Nutrition and Exercise Metabolism*, *28*(5), 464–467. <https://doi.org/10.1123/ijsnem.2016-0315>
- Bullough, R. C., Gillette, C. A., Harris, M. A., & Melby, C. L. (1995). Interaction of acute changes in exercise energy expenditure and energy intake on resting metabolic rate. *American Journal of Clinical Nutrition*, *61*(3), 473–481. <https://doi.org/10.1093/ajcn/61.3.473>
- Cameron, V. A., Autelitano, D. J., Evans, J. J., Ellmers, L. J., Espiner, E. A., Gary Nicholls, M., & Mark Richards, A. (2002). Body-size dependence of resting energy expenditure can be attributed to nonenergetic homogeneity of fat-free mass. *American Journal of Physiology - Endocrinology and Metabolism*, *282*(1), E132-138. <https://doi.org/10.1152/AJPENDO.2002.282.1.E132/ASSET/IMAGES/LARGE/H10120627008.JPEG>
- Compher, C., Frankenfield, D., Keim, N., & Roth-Yousey, L. (2006). Best practice methods to apply to measurement of resting metabolic rate in adults: a systematic review. *Journal of the American Dietetic Association*, *106*(6), 881–903. <https://doi.org/10.1016/J.JADA.2006.02.009>
- Costello, J. T., Bieuzen, F., & Bleakley, C. M. (2014). Where are all the female participants in Sports and Exercise Medicine research? *European Journal of Sport Science*, *14*(8), 847–851. <https://doi.org/10.1080/17461391.2014.911354>
- Cunningham, J. (1982). Body composition and resting metabolic rate: The myth of feminine metabolism. *American Journal of Clinical Nutrition*, *36*(4), 721–726. <https://doi.org/10.1093/ajcn/36.4.721>
- Cunningham, J. (1991). Body composition as a determinant of energy expenditure: a synthetic review and a proposed general prediction equation. *Am J Clin Nutr*, *54*(6), 963–969.
- Day, D. S., Gozansky, W. S., Van Pelt, R. E., Schwartz, R. S., & Kohrt, W. M. (2005). Sex hormone suppression reduces resting energy expenditure and β -adrenergic support of resting energy expenditure. *Journal of Clinical Endocrinology and Metabolism*, *90*(6), 3312–3317. <https://doi.org/10.1210/JC.2004-1344>

- De Souza, M. J. (2003). Menstrual disturbances in athletes: A focus on luteal phase defects. *Medicine and Science in Sports and Exercise*, 35(9), 1553–1563. <https://doi.org/10.1249/01.MSS.0000084530.31478.DF>
- De Souza, M. J., Toombs, R. J., Scheid, J. L., O'Donnell, E., West, S. L., & Williams, N. I. (2010). High prevalence of subtle and severe menstrual disturbances in exercising women: Confirmation using daily hormone measures. *Human Reproduction*, 25(2), 491–503. <https://doi.org/10.1093/humrep/dep411>
- Diffey, B., Piers, L. S., Soares, M. J., & O'dea, K. (1997). The effect of oral contraceptive agents on the basal metabolic rate of young women. *British Journal of Nutrition*, 77(6), 853–862. <https://doi.org/10.1079/bjn19970084>
- Duhita, M. R., Schutz, Y., Montani, J. P., Dulloo, A. G., & Miles-Chan, J. L. (2017). Oral contraceptive pill alters acute dietary protein-induced thermogenesis in young women. *Obesity*, 25(9), 1482–1485. <https://doi.org/10.1002/OBY.21919>
- Duhita, M. R., Schutz, Y., Montani, J. P., Dulloo, A. G., & Miles-Chan, J. L. (2019). Assessment of the dose-response relationship between meal protein content and postprandial thermogenesis: Effect of sex and the oral contraceptive pill. *Nutrients*, 11(7), 1599. <https://doi.org/10.3390/NU11071599>
- Eck, L. H., Bennett, A. G., Egan, B. M., Ray, J. W., Mitchell, C. O., Smith, M. A., & Klesges, R. C. (1997). Differences in macronutrient selections in users and nonusers of an oral contraceptive. *The American Journal of Clinical Nutrition*, 65(2), 419–424. <https://doi.org/10.1093/AJCN/65.2.419>
- Elliott, K. J., Cable, N. T., & Reilly, T. (2005). Does oral contraceptive use affect maximum force production in women? *British Journal of Sports Medicine*, 39(1), 15–19. <https://doi.org/10.1136/bjism.2003.009886>
- Elliott-Sale, K. J., Minahan, C. L., Janse de Jonge, X. A. K., Ackerman, K. E., Sipila, S., Constantini, N. W., Lebrun, C. M., & Hackney, A. C. (2021). Methodological considerations for studies in sport and exercise science with women as participants: A working guide for standards of practice for research on women. *Sports Medicine*, 51(5), 843–861. <https://doi.org/10.1007/s40279-021-01435-8>
- Fischer, M. A. (2008). Implanon: A new contraceptive implant. *JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing*, 37(3), 361–368. <https://doi.org/10.1111/j.1552-6909.2008.00247.x>
- Gavin, K. M., Kohrt, W. M., Klemm, D. J., & Melanson, E. L. (2018). Modulation of energy expenditure by estrogens and exercise in women. *Exercise and Sport Sciences Reviews*, 46(4), 232. <https://doi.org/10.1249/JES.0000000000000160>
- Goran, M. I., Calles-Escandon, J., Poehlman, E. T., O'Connell, M., & Danforth, E. (1994). Effects of increased energy intake and/or physical activity on energy expenditure in young healthy men. *Journal of Applied Physiology*, 77(1), 366–372. <https://doi.org/10.1152/jappl.1994.77.1.366>
- Gould, L. M., Cabre, H. E., Brewer, G. J., Hirsch, K. R., Blue, M. N. M., & Smith-Ryan, A. E. (2021). Impact of follicular menstrual phase on body composition measures and resting metabolism. *Medicine and Science in Sports and Exercise*, 53(11), 2396–2404. <https://doi.org/10.1249/MSS.0000000000002702>
- Harris, J. A., & Benedict, F. G. (1918). A biometric study of human basal metabolism. *Proceedings of the National Academy of Sciences of the United States of America*, 4(12), 370–373. <https://doi.org/10.1073/PNAS.4.12.370>

- Hirschberg, A. L. (2022). Challenging aspects of research on the influence of the menstrual cycle and oral contraceptives on physical performance. *Sports Medicine*, 52(7), 1453–1456. <https://doi.org/10.1007/s40279-021-01616-5>
- Hulbert, A. J., & Else, P. L. (2004). Basal metabolic rate: History, composition, regulation, and usefulness. *Physiological and Biochemical Zoology*, 77(6), 869–876.
- Jensen, M. D., & Levine, J. (1998). Effects of oral contraceptives on free fatty acid metabolism in women. *Metabolism: Clinical and Experimental*, 47(3), 280–284. [https://doi.org/10.1016/S0026-0495\(98\)90257-8](https://doi.org/10.1016/S0026-0495(98)90257-8)
- Jürimäe, J., Vaiksaar, S., Mäestu, J., Purge, P., & Jürimäe, T. (2011). Adiponectin and bone metabolism markers in female rowers: Eumenorrhic and oral contraceptive users. *Journal of Endocrinological Investigation*, 34(11), 835–839. <https://doi.org/10.3275/7415>
- King, L. A., Michels, K. A., Graubard, B. I., & Trabert, B. (2021). Trends in oral contraceptive and intrauterine device use among reproductive-aged women in the US from 1999 to 2017. *Cancer Causes & Control*, 32(6), 587–595. <https://doi.org/10.1007/S10552-021-01410-8>
- Koehler, K., Williams, N. I., Mallinson, R. J., Southmayd, E. A., Allaway, H. C. M., & De Souza, M. J. (2016). Low resting metabolic rate in exercise-associated amenorrhea is not due to a reduced proportion of highly active metabolic tissue compartments. *American Journal of Physiology - Endocrinology and Metabolism*, 311(2), E480–E487. <https://doi.org/10.1152/ajpendo.00110.2016>
- Koşar, Ş. N., Güzel, Y., Köse, M. G., Kin İşler, A., & Hazır, T. (2022). Whole and segmental body composition changes during mid-follicular and mid-luteal phases of the menstrual cycle in recreationally active young women. *Annals of Human Biology*, 49(2), 124–132. <https://doi.org/10.1080/03014460.2022.2088857>
- Krenitsky, J. (2005). Adjusted body weight, pro: Evidence to support the use of adjusted body weight in calculating calorie requirements. *Nutrition in Clinical Practice*, 20(4), 468–473. <https://doi.org/10.1177/0115426505020004468>
- Kuikman, M. A., McKay, A. K. A., Smith, E. S., Ackerman, K. E., Harris, R., Elliott-sale, K. J., Stellingwerff, T., & Burke, L. M. (2023). Female athlete representation and dietary control methods among studies assessing chronic carbohydrate approaches to training. *International Journal of Sport Nutrition & Exercise Metabolism*, 33(4), 198–208. <https://doi.org/10.1123/ijsnem.2022-0214>
- Kuikman, M. A., Smith, E. S., McKay, A. K. A., Ackerman, K. E., Harris, R., Elliott-Sale, K. J., Stellingwerff, T., & Burke, L. M. (2023). Fueling the Female Athlete: Auditing Her Representation in Studies of Acute Carbohydrate Intake for Exercise. *Medicine and Science in Sports and Exercise*, 55(3), 569–580. <https://doi.org/10.1249/MSS.0000000000003056>
- Loucks, A. B., Kiens, B., & Wright, H. H. (2011). Energy availability in athletes. *Journal of Sports Sciences*, 29(SUPPL. 1), S7-15. <https://doi.org/10.1080/02640414.2011.588958>
- Malo-Vintimilla, L., Aguirre, C., Vergara, A., Fernández-Verdejo, R., & Galgani, J. E. (2023). Resting energy metabolism and sweet taste preference during the menstrual cycle in healthy women. *British Journal of Nutrition*, 1–19. <https://doi.org/10.1017/S0007114523001927>
- Martin, D., Sale, C., Cooper, S. B., & Elliott-Sale, K. J. (2018). Period prevalence and perceived side effects of hormonal contraceptive use and the menstrual cycle in elite athletes. *International Journal of Sports Physiology and Performance*, 13(7), 926–932. <https://doi.org/10.1123/ijsp.2017-0330>

- McKay, A. K. A., Minahan, C., Harris, R., McCormick, R., Skinner, J., Ackerman, K. E., & Burke, L. M. (2023). Female Athlete Research Camp: A unique model for conducting research in high performance female athletes. *Medicine and Science in Sport and Exercise*.
- McKay, A. K. A., Stellingwerff, T., Smith, E. S., Martin, D. T., Mujika, I., Goosey-Tolfrey, V. L., Sheppard, J., & Burke, L. M. (2022). Defining training and performance caliber: A participant classification framework. *International Journal of Sports Physiology and Performance*, 17(2), 317–331. <https://doi.org/10.1123/IJSPP.2021-0451>
- McNamara, A., Harris, R., & Minahan, C. (2022). ‘That time of the month’ ... for the biggest event of your career! Perception of menstrual cycle on performance of Australian athletes training for the 2020 Olympic and Paralympic Games. *BMJ Open Sport — Exercise Medicine*, 8(2), e001300. <https://doi.org/10.1136/BMJSEM-2021-001300>
- Melanson, E. L., Gavin, K. M., Shea, K. L., Wolfe, P., Wierman, M. E., Schwartz, R. S., & Kohrt, W. M. (2015). Regulation of energy expenditure by estradiol in premenopausal women. *Journal of Applied Physiology*, 119(9), 975. <https://doi.org/10.1152/JAPPLPHYSIOL.00473.2015>
- Melin, A., Tornberg, Å. B., Skouby, S., Faber, J., Ritz, C., Sjödin, A., & Sundgot-Borgen, J. (2014). The LEAF questionnaire: A screening tool for the identification of female athletes at risk for the female athlete triad. *British Journal of Sports Medicine*, 48(7), 540–545. <https://doi.org/10.1136/bjsports-2013-093240>
- Melin, A., Tornberg, B., Skouby, S., Møller, S. S., Sundgot-Borgen, J., Faber, J., Sidemann, J. J., Aziz, M., & Sjödin, A. (2015). Energy availability and the female athlete triad in elite endurance athletes. *Scandinavian Journal of Medicine and Science in Sports*, 25(5), 610–622. <https://doi.org/10.1111/sms.12261>
- Mihm, M., Gangooly, S., & Muttukrishna, S. (2011). The normal menstrual cycle in women. *Animal Reproduction Science*, 124(3–4), 229–236. <https://doi.org/10.1016/j.anireprosci.2010.08.030>
- Myerson, M., Gutin, B., Warren, M. P., May, M. T., Contento, I., Lee, M., Pi-Sunyer, F. X., Pierson, R. N., & Brooks-Gunn, J. (1991). Resting metabolic rate and energy balance in amenorrheic and eumenorrheic runners. *Medicine and Science in Sports and Exercise*, 23(1), 15–22. <https://doi.org/10.1249/00005768-199101000-00004>
- Ong, J. N., Ducker, K. J., Furzer, B. J., Dymock, M., & Landers, G. J. (2022). Measures of body composition via Dual-energy X-ray absorptiometry, ultrasound and skinfolds are not impacted by the menstrual cycle in active eumenorrheic females. *Journal of Science and Medicine in Sport*, 25(2), 115–121. <https://doi.org/10.1016/j.jsams.2021.09.192>
- Oxfeldt, M., Dalgaard, L. B., Jørgensen, A. A., & Hansen, M. (2020). Hormonal contraceptive use, menstrual dysfunctions, and self-reported side effects in elite athletes in Denmark. *International Journal of Sports Physiology and Performance*, 15(10), 1377–1384. <https://doi.org/10.1123/ijsp.2019-0636>
- Paris, H. L., Foright, R. M., Werth, K. A., Larson, L. C., Beals, J. W., Cox-York, K., Bell, C., & Melby, C. L. (2016). Increasing energy flux to decrease the biological drive toward weight regain after weight loss - A proof-of-concept pilot study. *Clinical Nutrition ESPEN*, 11, e12–e20. <https://doi.org/10.1016/j.clnesp.2015.11.005>
- Pelkman, C. L., Chow, M., Heinbach, R. A., & Rolls, B. J. (2001). Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. *The American Journal of Clinical Nutrition*, 73(1), 19–26. <https://doi.org/10.1093/AJCN/73.1.19>

- Pietrobelli, A., Formica, C., Wang, Z., & Heymsfield, S. B. (1996). Dual-energy X-ray absorptiometry body composition model: review of physical concepts. *American Journal of Physiology - Endocrinology and Metabolism*, 271(6 Pt 1), E941-51.
- Schofield, K. L., Thorpe, H., & Sims, S. T. (2019). Resting metabolic rate prediction equations and the validity to assess energy deficiency in the athlete population. *Experimental Physiology*, 104(4), 469–475. <https://doi.org/10.1113/EP087512>
- Siedler, M. R., De Souza, M. J., Albracht-Schulte, K., Sekiguchi, Y., & Tinsley, G. M. (2023). The influence of energy balance and availability on resting metabolic rate: Implications for assessment and future research directions. *Sports Medicine*, 53(8), 1507–1526. <https://doi.org/10.1007/s40279-023-01856-7>
- Slater, G., Farley, A., Hogarth, L., Areta, J. L., Paulsen, G., & Garthe, I. (2023). Impact of 24-Hr diet and physical activity control on short-term precision error of dual-energy x-ray absorptiometry physique assessment. *International Journal of Sport Nutrition and Exercise Metabolism*, 33(1), 30–38. <https://doi.org/10.1123/ijsnem.2022-0125>
- Slater, G., Townsend, N., Morabito, A., Burke, L., Schultz, C., Brookes, D., Farley, A., Meerkin, J., & Ducker, K. (2023). *Australian high performance sport system: Practitioner Best Practice Guidelines for DXA Assessment of Body Composition*.
- Smith, E. S., McKay, A. K. A., Kuikman, M., Ackerman, K. E., Harris, R., Elliott-Sale, K. J., Stellingwerff, T., & Burke, L. M. (2022). Auditing the representation of female versus male athletes in sports science and sports medicine research: Evidence-based performance supplements. *Nutrients*, 14(5), 953. <https://doi.org/10.3390/NU14050953>
- Stachenfeld, N. S. (2008). Sex hormone effects on body fluid regulation. *Exercise and Sport Sciences Reviews*, 36(3), 152–159. <https://doi.org/10.1097/JES.0b013e31817be928>
- Stellingwerff, T., Mountjoy, M., McClusky, W. T. P., & et al. (2023). A review of the scientific rationale, development, and validation of the IOC Relative Energy Deficiency in Sport Clinical Assessment Tool - Version 2 (IOC REDs CAT2): by a sub-group of the IOC consensus on REDs. *British Journal of Sports Medicine, In Press*, 1110–1123. <https://doi.org/10.1136/bjsports-2023-106914>
- Sterringer, T., & Larson-Meyer, D. E. (2022). RMR ratio as a surrogate marker for low energy availability. *Current Nutrition Reports*, 1, 1–10. <https://doi.org/10.1007/S13668-021-00385-X/TABLES/2>
- Steward, R. G., Bateman, L. A., Slentz, C., Stanczyk, F. Z., & Price, T. M. (2016). The impact of short-term depot-medroxyprogesterone acetate treatment on resting metabolic rate. *Contraception*, 93(4), 317–322. <https://doi.org/10.1016/J.CONTRACEPTION.2016.01.001>
- St-Onge, M. P., Wang, Z. M., Horlick, M., Wang, J., & Heymsfield, S. B. (2004). Dual-energy X-ray absorptiometry lean soft tissue hydration: Independent contributions of intra- and extracellular water. *American Journal of Physiology - Endocrinology and Metabolism*, 287(5), 842–847. <https://doi.org/10.1152/ajpendo.00361.2003>
- Strock, N. C. A., Koltun, K. J., Southmayd, E. A., Williams, N. I., & Souza, M. J. De. (2020). Indices of resting metabolic rate accurately reflect energy deficiency in exercising women. *International Journal of Sport Nutrition and Exercise Metabolism*, 30(1), 14–24. <https://doi.org/10.1123/ijsnem.2019-0199>
- Thompson, B. M., Hillebrandt, H. L., Sculley, D. V., Barba-Moreno, L., & Janse de Jonge, X. A. K. (2021). The acute effect of the menstrual cycle and oral contraceptive cycle on measures of body composition. *European Journal of Applied Physiology*, 121(11), 3051–3059. <https://doi.org/10.1007/s00421-021-04771-9>

- Trexler, E. T., Smith-Ryan, A. E., & Norton, L. E. (2014). Metabolic adaptation to weight loss: Implications for the athlete. *Journal of the International Society of Sports Nutrition*, *11*(1), 1–7. <https://doi.org/10.1186/1550-2783-11-7>
- Vigil, P., Meléndez, J., Petkovic, G., & Del Río, J. P. (2022). The importance of estradiol for body weight regulation in women. *Frontiers in Endocrinology*, *13*, 951186. <https://doi.org/10.3389/fendo.2022.951186>
- Weinsier, R. L., Schutz, Y., & Bracco, D. (1992). Reexamination of the relationship of resting metabolic rate to fat-free mass and to the metabolically active components of fat-free mass in humans. *American Journal of Clinical Nutrition*, *55*(4), 790–794. <https://doi.org/10.1093/ajcn/55.4.790>

Table 1 Baseline athlete characteristics with menstrual status with body mass, lean body mass, fat free mass and fat mass from first dual-energy X-ray absorptiometry scan.

	NC	HC
Age (yrs)	20.8±3.2	22.4±3.5
Menarche (yrs)	13.0±2.0	12.9±1.6
BMI (kg/m ²)	27.1±3.4	28.4±5.0
Body mass (kg)	70.8±8.1	79.1±14.2
Lean body mass (kg)	45.0±2.5	49.9±4.7
Fat free mass (kg)	47.6±2.6	52.8±4.9
Fat mass (kg)	23.2±7.2	26.6±10.9

Note. Data are presented as mean±SD. NC, naturally cycling athletes; HC, hormonal contraceptive users.

Table 2: Equations used to calculate RMR_{ratio} and relative RMR, and low energy availability indicators with corresponding threshold to indicate a suppressed RMR or low energy availability

RMR equation		Threshold	LEA Indicator	Threshold
HB	$RMR_M \div ((655.1 + (9.563 \times BM) + (1.850 \times Ht)) - (4.676 \times Age))$	<0.90	Total cholesterol	>5.2 mmol/L
ABM in HB	$RMR_M \div ((655.1 + (9.563 \times ABM) + (1.850 \times Ht)) - (4.676 \times Age))$	<0.90	LDL	>3.4 mmol/L
Cunningham ₁₉₈₀	$RMR_M \div (500 + (22 \times LBM))$	<0.90	Cortisol	>620 nmol/L
Cunningham ₁₉₉₁	$RMR_M \div (370 + (21.6 \times FFM))$	<0.92	T3 and IGF-1	Within or below lowest quartile*
Relative RMR	$RMR_M \div FFM$	$<30 \text{ kcal} \cdot \text{kgFFM}^{-1} \cdot \text{day}^{-1}$	LEAF-Q Score	>8

Note. RMR, resting metabolic rate; RMR_M , Measured RMR; HB, Harris, Benedict; BM, body mass; Ht, height; ABM, adjusted body mass; LBM, lean body mass; FFM, fat free mass; LEA, low energy availability; LDL, low density lipoprotein; T3, triiodothyronine; IGF-1, insulin-like growth factor 1; LEAF-Q; Low Energy Availability in Females Questionnaire. *Using lab-specific age dependent range.

Table 3: Energy and macronutrient intake during the standardised diet period the day prior to testing during Phase 1, Phase 2, and Phase 4 of the menstrual cycle for naturally cycling athletes and hormonal contraceptive users.

	Phase 1		Phase 2		Phase 4		P		
	NC	HC	NC	HC	NC	HC	Phase	MS	Interaction
Energy (kcal)	1943±162	2108±315	1968±202	1997±183	1947±157	2030±162	0.527	0.215	0.286
Carbohydrate (g)	271±24	295±34	268±36	288±18	275±24	290±23	0.402	0.055	0.565
Carbohydrate (g/kg)	4.0±0.2	4.1±0.3	4.0±0.5	4.1±0.3	4.1±0.3	4.1±0.1	0.447	0.672	0.451
Protein (g)	83±9	93±17	86±11	86±10	83±7	87±6	0.581	0.181	0.221
Protein (g/kg)	1.2±0.1	1.3±0.2	1.3±0.1	1.2±0.1	1.2±0.1	1.2±0.1	0.555	0.668	0.191
Fat (g)	57±7	61±14	60±19	55±9	56±5	57±5	0.526	0.955	0.259
Fat (g/kg)	0.9±0.1	0.9±0.2	0.9±0.3	0.8±0.1	0.8±0.1	0.8±0.1	0.522	0.131	0.249

Note. Data are presented as mean±SD. NC, naturally cycling athletes; HC, hormonal contraceptive users; MS, menstrual status.

Table 4: Serum estradiol and progesterone concentrations during Phase 1, and Phase 4 of the menstrual cycle for naturally cycling athletes and hormonal contraceptive users.

	Phase 1		Phase 4	
	NC	HC	NC	HC
Estradiol (pg/mL)	26.3±3.9	57.1±58.9	159.1±63.0*	42.9±30.4
Progesterone (nmol/L)	1.4±0.6	1.7±1.9	43.0±37.9*	2.57±2.8

Note: Data are presented as mean±SD. *Indicates significant difference from Phase 1 and compared to HC users. NC, naturally cycling athletes; HC, hormonal contraceptive users

Table 5. Resting metabolic rate ratio (measured:predicted) calculated with the Harris Benedict, Cunningham 1980 and Cunningham 1991 equation during Phase 1, and Phase 4 of the menstrual cycle for naturally cycling athletes and hormonal contraceptive users.

	Phase 1		Phase 4	
	NC	HC	NC	HC
Harris Benedict	1.05±0.04	1.08±0.11	1.05±0.06	1.07±0.08
Harris Benedict with ABM (<i>n</i> =3 NC/5HC)	1.09±0.06	1.11±0.07	1.08±0.03	1.18±0.03
Cunningham ₁₉₈₀	1.09±0.07	1.08±0.07	1.08±0.08	1.08±0.08
Cunningham ₁₉₉₁	1.16±0.07	1.15±0.08	1.15±0.09	1.14±0.09

Note: Data are presented as mean±SD. NC, naturally cycling athletes; HC, hormonal contraceptive users; ABM, adjusted body mass.

Figure 1: Overview of experimental protocol with measurements occurring during Phase 1, Phase 2, and Phase 4 of the menstrual cycle in naturally cycling athletes (A) and measurements occurring during three spaced occasions for hormonal contraceptive users. For combined-monophasic oral contraceptive users, testing occurred on active pill-taking days. For all other hormonal contraceptive users (injection and implant), testing occurred at any given time (B).

Figure 2: Absolute resting metabolic rate (A), and relative resting metabolic rate (D) with menstrual cycle phase and hormonal contraceptive usage. Data shown as mean with individual data points.

Figure 3: Fat mass estimates (A) fat free mass estimates (B), and lean body mass estimates (D) with menstrual cycle phase and hormonal contraceptive usage. Data shown as mean with individual data points. *Indicates significant difference between groups.

Figure 4: Repeated measures correlation between relative resting metabolic rate (RMR) and serum estradiol concentrations (A), serum progesterone concentrations (B) and the concentration of estradiol to progesterone ratio (C). Each coloured line represents an individual naturally cycling athlete with Phase 1, Phase 2, and Phase 4 measurements (n=11).

Figure 5: Number of athletes who presented with a suppressed RMR or menstrual irregularity across the training camp, and indicators of low energy availability within each cohort. *Note.*

HC, hormonal contraceptive; NC, naturally cycling; RMR, resting metabolic rate; LEAF-Q, the Low Energy Availability in Females Questionnaire; TC, total cholesterol; LDL, low-density lipoprotein; T3, triiodothyronine